PT Itama Ranoraya Tbk (IRRA), in the first semester of 2021, posted revenues of Rp565.2 billion, an increase of 611.6% compared to the same period last year of Rp79.4 billion.

President Director of IRRA, Heru Firdausi Syarif, said that along with revenue, net profit jumped by around 1.271% to Rp50.8 billion, compared to the same period in 2020 which was Rp3.7 billion.

"Revenue and net profit in the first semester were very good, especially the increase in contributions from the private sector and retail, which was in line with our plan or target. We are optimistic that it will continue in the second semester," in his statement, Thursday (5/8).

The increase in the company's sales came from sales to the retail segment (non-government budget) or non-government.

In addition, sales growth also lies in non-electromedical medical devices and in vitro diagnostic products.

In-Vitro products increased by around 613.9%, with the C